TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ Study
Latest Information Update: 27 Nov 2023
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; TQB 2868 (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 20 Nov 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Aug 2023 New trial record